Reduced probability of improving viro-immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort study.
HIV
antiretroviral therapy
discontinuation
vertical transmission
viro-immunological effectiveness
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
18
01
2023
received:
30
09
2022
accepted:
19
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Young adults with vertical transmission (VT) of human immunodeficiency virus (HIV) represent a fragile population. This study evaluates factors associated with viro-immunological outcome of these patients. We performed a multicenter study including HIV-infected subjects with VT ≥ 18 years old from six Italian clinics. Subjects were observed from birth to death, lost to follow-up, or last visit until December 31, 2019. Condition of "optimal viro-immunological status" (OS) was defined as the simultaneous presence of HIV ribonucleic acid (RNA) < 50 copies/mL, CD4+ > 500 cells/mm A total of 126 subjects were enrolled. At 18 years of age, 52/126 (44.4%) had HIV-RNA > 50 copies/mL, 47/126 (38.2%) had CD4+ < 500/mm Only a small proportion of subjects with VT of HIV reached the adult age with "OS". Transition to the adult care with a compromised viro-immunological condition represents a negative driver for future optimal infection control, with a higher risk of discontinuation of cART and a reduced probability to improve the immunological status later in the years.
Identifiants
pubmed: 36840488
doi: 10.1002/iid3.778
pmc: PMC9910169
doi:
Substances chimiques
RNA
63231-63-0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e778Informations de copyright
© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Clin Microbiol Infect. 2012 May;18(5):449-58
pubmed: 21919996
BMC Pediatr. 2021 Nov 20;21(1):519
pubmed: 34798840
AIDS Res Hum Retroviruses. 2018 Mar;34(3):241-243
pubmed: 29061072
Lancet HIV. 2015 Mar;2(3):e98-106
pubmed: 26424550
BMC Public Health. 2020 Mar 30;20(1):416
pubmed: 32228523
J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):240-247
pubmed: 33074855
J Int AIDS Soc. 2019 Aug;22(8):e25386
pubmed: 31441211
J Clin Virol. 2019 Jul;116:23-28
pubmed: 31075548
J Clin Med. 2021 Nov 22;10(22):
pubmed: 34830737
AIDS Patient Care STDS. 2011 Jul;25(7):413-22
pubmed: 21992620
J Int AIDS Soc. 2021 Oct;24(10):e25804
pubmed: 34672108
Clin Immunol. 2021 Aug;229:108773
pubmed: 34102315
Clin Microbiol Infect. 2019 Nov;25(11):1443-1446
pubmed: 31352080
AIDS Care. 2016;28(5):561-5
pubmed: 26766017
Patient Prefer Adherence. 2018 Nov 30;12:2545-2551
pubmed: 30555224
Ann Intern Med. 2018 Sep 18;169(6):376-384
pubmed: 30140916
J Int AIDS Soc. 2017 May 16;20(Suppl 3):21528
pubmed: 28530039
AIDS. 2020 Feb 1;34(2):261-266
pubmed: 31651427
Clin Infect Dis. 2021 Jul 1;73(1):50-59
pubmed: 34370842
HIV Res Clin Pract. 2019 Feb;20(1):1-11
pubmed: 31303148
J Infect Public Health. 2018 Mar - Apr;11(2):265-269
pubmed: 28826735
Clin Infect Dis. 2016 Oct 15;63(8):1105-1112
pubmed: 27439528
AIDS. 2019 Oct 1;33(12):1923-1934
pubmed: 31274538
J Glob Antimicrob Resist. 2015 Dec;3(4):267-272
pubmed: 27842871
JAMA. 2000 Jul 12;284(2):190-7
pubmed: 10889592
PeerJ. 2018 May 25;6:e4848
pubmed: 29844989
World J Pediatr. 2019 Oct;15(5):492-498
pubmed: 31286425
PLoS One. 2019 Feb 14;14(2):e0212283
pubmed: 30763363